What is the optimal rodent model for anti-tumor drug testing?

Cancer and Metastasis Reviews

Volumn 17, Issue 3, 1998, Pages 301-304

  Kerbel, Robert S ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; GREEN FLUORESCENT PROTEIN; NEW DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER TRANSPLANTATION; DRUG SCREENING; FLUORESCENCE; GENETIC ENGINEERING; HUMAN; HUMAN TISSUE; METASTASIS; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE; TUMOR MODEL;

EID: 0032424179     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006152915959     Document Type: Review

References (26)

1. Marsoni S, Wittes R: Clinical development of anticancer agents - A National Cancer Institute perspective: A commentary. Cancer Treat Rep 68: 77, 1984
2. Nomura T, Sakurai Y, Inaba M (eds): The Nude Mouse and Anticancer Drug Evaluation. Kawasaki and Tokyo: Jointly by Central Institute for Experimental Animals and Japanese Journal of Cancer and Chemotherapy Publishers Inc. Tokyo, 1996
3. Fiebig HH, Berger DP: Boven E, Winograd B (eds): The Nude Mouse in Oncology Research. Boca Raton: CRC Press, 1995, Preclinical phase II trials. pp 318-235
4. Inaba M, Kobayashi T, Tashiro T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, Nomura T: Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. Cancer 64: 1577-1582, 1989
5. Inaba M, Tashiro T, Kobayashi T, Sakurai Y, Mauro K, Ohnishi Y, Ueyama Y, Nomura T: Responsiveness of human gastric tumors impanted in nude mice to clinically equivalent doses of various antitumor agents. Jpn J Cancer Res 79: 517-522, 1988
6. Maru Y, Ueyama Y, Inaba M, Emura R, Ohnishi Y, Nakamura O, Sato O, Nomura T: Responsiveness of subcutaneous human glioma xenografts to various antitumor agents. Anticancer Res 10: 209-212, 1990
7. KiP1 on adhesion-dependent resistance of tumor cells to anticancer agents. Nature Med 2: 1204-1210, 1996
8. Berges RR, Vukanovic J, Epstein J, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh CT, Isaacs JT: Implication of cell kinetic changes during the progression of human prostatic carcinoma. Clin Cancer Res 1: 473-480, 1995
9. Hewitt HB: Animal tumor models and their relevance to human tumor immunology. J Biol Resp Modifiers 1: 107-119, 1982
10. Hewitt HB, Blake ER, Walder AS: A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 33: 241-259, 1976
11. Hewitt HB: The choice of animal tumors for experimental studies of cancer therapy. Adv Cancer Res 27: 149-200, 1978
12. Hewitt HB: A critical examination of the foundations of immunotherapy of cancer. Clin Radiol 30: 361-369, 1979
13. Wilmanns C, Fan D, O'Brian CA, Bucana CD, Fidler IJ: Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 52: 98-104, 1992
14. Willmanns C, Fan D, O'Brian CA, Radinsky R, Bucana CD, Tsan R, Fidler IJ: Modulation of doxorubicin sensitivity and level of P-glycoprotein expression in human colon carcinoma cells by ectopic and orthotopic environments in nude mice. Int J Cancer 3: 412-422, 1993
15. Radinsky R: Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 14: 323-338, 1995
16. Tontsch U, Bauer H: Glial cells and neurons induce blood-brain barrier related enzymes in cultured cerebral endothelial cells. Brain Res 539: 247-253, 1991
17. Fidler IJ, Wilmanns C, staroselsky A, Radinsky R, Dong Z, Fan D: Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 13: 209-222, 1994
18. Chishima T, Yang M, Miyagi Y, Li L, Tan Y, Baranov E, Shimada H, Moossa AR, Penman S, Hoffman RM: Governing step of metastasis visualized in vitro. Proc Natil Acad Sci USA 94: 11573-11576, 1997
19. Chishima T, Miyagi Y, Wang, X, Yamaoka H, Shimada H, Moossa AR, Hoffman RM: Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res 37: 2042-2047, 1997
20. Chishima T, Yang M, Miyagi Y, Li L, Tan Y, Baranov E, Shimada H, Moossa AR, Penman S, Hoffman RM: Host organ colonization, the governing step of metastasis, visualized in vivo by green fluorescent protein expression. [Abstract] Proc Am Assoc Cancer Res, 1998
21. Chishima T, Miyagi Y, Wang X, Baranov E, Tan Y, Yamaoka H, Shimada H, Moossa AR, Hoffman RM: Green fluorescent protein: A new light to study metastasis. [Abstract] Proc Am Assoc Cancer Res 1998
22. Dexter DL, Diamond M, Creveling J, Chen SF: Chemotherapy of mammary carcinomas arising in ras transgenic mice. Invest New Drugs 11: 161-168, 1993
23. Thomas H, Balkwill F: Assessing new anti-tumour agents and strategies in oncogene transgenic mice. Cancer Metastasis Rev 14: 91-95, 1995
24. Parangi S, O'Reilly MS, Christofori G, Holmgren L, Grosfeld J, Folkman J, Hanahan D: Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci (USA) 93: 2002-2007, 1996
25. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med 1: 792-797, 1995
26. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM: Inhibition of human tumor xenograft growth by treatment with the Farnesyl Transferase Inhibitor B956. Cancer Res 55: 5310-5314, 1995